Autologous Adipose-Derived Mesenchymal Stem Cells In Vitro Expanded

Autologous Adipose-Derived Mesenchymal Stem Cells (AD-MSCs) are at the forefront of innovative medical treatments. These cells, derived from a patient’s own fat tissue, are being studied in clinical trials for their potential to treat various conditions. This article focuses on two ongoing clinical trials investigating the use of AD-MSCs for urinary incontinence following prostate surgery and degenerative disc disease. These trials aim to evaluate the safety and effectiveness of this cutting-edge cellular therapy in addressing challenging medical conditions.

Related diseases and areas:

• Urinary incontinence
• Intervertebral disc degener…

Autologous Adipose-Derived Stem Cells

A groundbreaking clinical trial is exploring the use of autologous adipose-derived stem cells, specifically the NVD-003 osteogenic bone graft, to treat congenital pseudarthrosis of the tibia (CPT) in pediatric patients. This innovative approach aims to address a challenging condition that affects bone healing in children, offering hope for improved outcomes and quality of life.

Related diseases and areas:

• Lower limb fracture
• Congenital pseudarthrosis

Autologous Blood-Derived Endothelial Progenitor Cells, Haematopoietic Stem/Progenitor Cells, Activated Dendritic Cells And T Helper Cells

This article discusses an innovative clinical trial investigating the use of BGC101, a unique cell therapy composed of autologous blood-derived cells, for treating peripheral arterial disease (PAD) with critical limb ischemia (CLI). The study aims to evaluate the safety and effectiveness of this advanced therapy in patients who have not responded to standard treatments or are not candidates for further revascularization procedures.

Related diseases and areas:

• Peripheral arterial occlusi…

Autologous Bone Marrow-Derived Adult Mononuclear Cells, Not Expanded

This article discusses the use of Autologous Bone Marrow-Derived Adult Mononuclear Cells, Not Expanded, in clinical trials for treating dilated cardiomyopathy. This innovative approach involves using a patient’s own bone marrow cells to potentially improve heart function in those suffering from this serious cardiac condition. We’ll explore the details of a specific clinical trial, its objectives, and what this could mean for patients with dilated cardiomyopathy.

Related diseases and areas:

• Cardiomyopathy
• Dilated cardiomyopathy

Autologous Bone Marrow-Derived Mesenchymal Stem Cells

This article discusses a phase III clinical trial investigating the use of Autologous Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs) for treating knee osteoarthritis. The study compares the effectiveness of autologous and allogeneic mesenchymal stem cells against hyaluronic acid, a common treatment for this condition. We’ll explore the trial’s objectives, eligibility criteria, and potential implications for patients suffering from knee osteoarthritis.

Related diseases and areas:

• Osteoarthritis

AUTOLOGOUS BONE MARROW-DERIVED MONONUCLEAR CELLS

Clinical trials are studying AUTOLOGOUS BONE MARROW-DERIVED MONONUCLEAR CELLS in people with diabetic foot syndrome and chronic limb-threatening ischemia. These studies look at whether the treatment can improve tissue oxygen, wound healing, pain, and amputation outcomes, and they compare it with standard care or angioplasty.

Related diseases and areas:

• Diabetic foot
• Peripheral ischaemia
• Peripheral arterial occlusi…

Autologous CD34+ cells transduced with lentiviral vector encoding the human beta globin gene

Clinical trials of AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING THE HUMAN BETA-GLOBIN GENE are studying gene therapy in people with transfusion-dependent beta-thalassemia. The main goal is to check safety and whether treatment can help patients become free from regular blood transfusions. The trial includes pediatric and adult patients.

Autologous Cd34+ Cells Transduced With The G1Xcgd Lentiviral Vector Containing The Human Cybb Gene

This article discusses an innovative gene therapy approach for treating X-Linked Chronic Granulomatous Disease (X-CGD). The treatment involves using autologous CD34+ cells transduced with the G1XCGD lentiviral vector containing the human CYBB gene. This phase I/II clinical trial aims to evaluate the safety and efficacy of this gene therapy in patients with X-CGD, potentially offering a new treatment option for this rare genetic disorder.

Related diseases and areas:

• Chronic granulomatous disease

AUTOLOGOUS CD34+ ENRICHED CELL FRACTION THAT CONTAINS CD34+ CELLS TRANSDUCED WITH RETROVIRAL VECTOR THAT ENCODES FOR THE HUMAN ADA CDNA SEQUENCE

Clinical trials are studying AUTOLOGOUS CD34+ ENRICHED CELL FRACTION THAT CONTAINS CD34+ CELLS TRANSDUCED WITH RETROVIRAL VECTOR THAT ENCODES FOR THE HUMAN ADA CDNA SEQUENCE in people with ischemic stroke. The trial aims to see whether this treatment can affect recovery, especially infarct volume after stroke, and it is being tested in a phase 2 study in adults with acute ischemic stroke.

Related diseases and areas:

• Ischaemic stroke

Autologous Cd34+ Haematopoietic Stem And Progenitor Cells Transduced With A Lentiviral Vector Containing The Human Dclre1C Gene

This article discusses a Phase 1/2 clinical trial investigating the use of ARTEGENE, a gene therapy drug for treating Severe Combined Immunodeficiency (SCID) caused by mutations in the Artemis gene. The study aims to evaluate the safety and effectiveness of this innovative treatment approach for young patients with this rare and severe immune disorder.

Related diseases and areas:

• Combined immunodeficiency

Autologous Cd34+ Haematopoietic Stem And Progenitor Cells Transduced With A Lentiviral Vector Encoding The Interferon Alpha-2 Gene

This article explores the use of Temferon, an innovative gene therapy drug, in clinical trials for treating metastatic renal cell carcinoma (RCC) and glioblastoma multiforme (GBM). Temferon consists of autologous CD34+ hematopoietic stem and progenitor cells that have been genetically modified to produce interferon alpha-2. These trials aim to evaluate the safety, biological response, and efficacy of this groundbreaking treatment approach for patients with advanced cancers who have exhausted standard treatment options.

Related diseases and areas:

• Clear cell renal cell carci…
• Glioblastoma multiforme

Autologous Cd34+ Haematopoietic Stem Cells Genetically Modified With Lentiviral Vector Encoding The Cd18 Gene

This article discusses a clinical trial investigating the long-term safety and effectiveness of a gene therapy treatment for Leukocyte Adhesion Deficiency-I (LAD-I). The study focuses on a drug called RP-L201, which uses genetically modified stem cells to treat this rare genetic disorder. Patients who previously participated in an earlier phase of the trial are being followed for up to 15 years to monitor the treatment’s long-term effects and potential benefits.

Related diseases and areas:

• Leukocyte adhesion deficiency

Autologous Cd34+ Hematopoietic Stem Cells Transduced Ex Vivo With A Lentiviral Vector Encoding The Codon-Optimized Version Of Pklr Gene

This article discusses clinical trials using a novel gene therapy approach for treating Pyruvate Kinase Deficiency (PKD). The therapy involves autologous CD34+ hematopoietic stem cells that have been genetically modified with a lentiviral vector carrying the codon-optimized version of the PKLR gene. These trials aim to evaluate the safety and potential effectiveness of this innovative treatment for both adult and pediatric patients with PKD, a rare inherited disorder affecting red blood cell survival.

Related diseases and areas:

• Pyruvate kinase deficiency …

Autologous Cd34+Enriched Cells From Patients With Fanconi Anemia Subtype A Transduced Ex Vivo With Lentiviral Vector Carrying The Fanconi Anemia Complementation Group A Gene

Clinical trials are underway to evaluate the long-term safety and effectiveness of a novel gene therapy approach for patients with Fanconi Anemia Subtype A (FA-A). This therapy, known as RP-L102, involves using the patient’s own blood-forming stem cells, which are genetically modified to carry a corrected version of the FANCA gene. These trials aim to assess the potential of this treatment to improve blood cell production and reduce the risk of bone marrow failure and cancer in FA-A patients over an extended period.

Related diseases and areas:

• Congenital aplastic anaemia

Autologous Chondrocytes

Clinical trials investigating Autologous Chondrocytes are studying treatment for knee cartilage lesions. These studies look at whether the approach can improve symptoms, function, and quality of life compared with standard care. The main target group is adults with symptomatic articular cartilage damage in the knee.

Related diseases and areas:

• Chondropathy

Autologous Cord Blood-Derived Dendritic Cells Loaded With Wt1 Peptide Pool

Clinical trials are studying Autologous Cord Blood-Derived Dendritic Cells Loaded With Wt1 Peptide Pool in children and young adults with acute myeloid leukemia. The trials are looking at safety and whether the vaccine may help lower relapse risk after cord blood transplant. They focus on patients with WT1-positive AML.

Related diseases and areas:

• Acute myeloid leukaemia

Autologous Cord Blood-Derived Mononuclear Cells

This article discusses an innovative clinical trial investigating the use of autologous cord blood-derived mononuclear cells as a potential treatment for newborns with hypoxic-ischemic encephalopathy (HIE). The study, known as NEOSTEM, aims to evaluate the safety, feasibility, and preliminary efficacy of this cell therapy in improving outcomes for affected infants. We’ll explore the key aspects of this trial, including its objectives, eligibility criteria, and potential implications for neonatal care.

Related diseases and areas:

• Hypoxic-ischaemic encephalo…

AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE

Clinical trials are studying AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE in people with lung cancer. These studies look at whether the treatment can help keep the cancer from growing after first treatment, and they measure outcomes such as safety and progression-free survival.

Autologous Enriched T Cells Retrovirally Transduced To Express Two Chimeric Antigen Receptors Targeting Cd19 And Cd22

This article discusses clinical trials using AUTO1, an innovative CAR T-cell therapy targeting CD19 and CD22 in patients with relapsed or refractory B-cell leukemia and lymphoma. AUTO1 is being studied in both pediatric and adult populations, offering hope for patients who have not responded to conventional treatments. The trials aim to evaluate the safety, efficacy, and long-term effects of this groundbreaking therapy.

Related diseases and areas:

• Acute lymphocytic leukaemia
• Non-Hodgkin’s lymphoma
• Lupus nephritis
• Systemic lupus erythematosus

AUTOLOGOUS HAEMATOPOIETIC STEM AND PROGENITOR CELL POPULATION CONTAINING CD34+ CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR ENCODING THE TCIRG1 CDNA EX VIVO EXPANDED

Clinical trials are investigating AUTOLOGOUS HAEMATOPOIETIC STEM AND PROGENITOR CELL POPULATION CONTAINING CD34+ CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR ENCODING THE TCIRG1 CDNA EX VIVO EXPANDED in children with autosomal recessive osteopetrosis caused by TCIRG1 gene mutations. These studies aim to assess safety, feasibility, and efficacy. The trial data focus on paediatric patients with this rare condition.

Autologous Human Adipose Perivascular Stromal Cells Genetically Modified To Secrete Soluble Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand

Clinical trials are investigating Autologous Human Adipose Perivascular Stromal Cells Genetically Modified To Secrete Soluble Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand in people with locally advanced pancreatic cancer. The study is looking at safety and early signs of efficacy when this cell-based gene therapy is given with standard chemotherapy. It focuses on patients with ductal adenocarcinoma of the pancreas that cannot be removed by surgery.

Related diseases and areas:

• Ductal adenocarcinoma of pa…
• Adenocarcinoma pancreas

AUTOLOGOUS KERATINOCYTES AND FIBROBLASTS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING COL7A1 CDNA

Clinical trials are studying AUTOLOGOUS KERATINOCYTES AND FIBROBLASTS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING COL7A1 CDNA in people with recessive dystrophic epidermolysis bullosa (RDEB). These trials mainly look at safety after grafting genetically corrected skin equivalents and follow patients over time to watch for side effects and longer-term outcomes.

Related diseases and areas:

• Epidermolysis bullosa

Autologous Mature Dendritic Cells Loaded With Autologous Tumor Lysate

This article discusses clinical trials using a novel treatment approach for newly diagnosed glioblastoma, a type of brain cancer. The treatment involves using a patient’s own immune cells, specifically mature dendritic cells loaded with the patient’s tumor lysate, as a vaccine. This personalized immunotherapy is being studied in combination with standard treatments to potentially improve survival outcomes for glioblastoma patients.

Related diseases and areas:

• Glioblastoma
• Glioblastoma multiforme

Autologous Microfat

This article explores an innovative clinical trial investigating the use of Autologous Microfat combined with Platelet-Rich Plasma (PRP) injections as a treatment for radiocarpal osteoarthritis. The study aims to compare this new approach with the established standard treatment of total wrist denervation, offering potential hope for patients suffering from this debilitating condition.

Related diseases and areas:

• Osteoarthritis

Autologous Oral Mucosa-Derived Adult Fibroblasts, Ex-Vivo Expanded

A groundbreaking clinical trial is underway to evaluate the safety and effectiveness of using autologous oral mucosa-derived adult fibroblasts, along with keratinocytes, in treating cleft palate. This advanced therapy product, known as BIOCLEFT, is a tissue-engineered nanostructured fibrin-agarose oral mucosa substitute that could potentially revolutionize cleft palate treatment in pediatric patients.

Related diseases and areas:

• Cleft lip and palate

Autologous Oral Mucosa-Derived Adult Keratinocytes, Ex-Vivo Expanded

A groundbreaking clinical trial is underway to evaluate the safety and feasibility of using autologous tissue-engineered nanostructured fibrin-agarose oral mucosa substitute for treating patients with cleft palate. This Phase I-IIa study focuses on a novel approach using the patient’s own oral mucosa-derived adult keratinocytes and fibroblasts, which are expanded in a laboratory setting. The trial aims to assess the potential benefits of this advanced therapy in improving outcomes for children with cleft lip and palate.

Related diseases and areas:

• Cleft lip and palate

Autologous Pancreatic Islets

This article explores the use of Autologous Pancreatic Islets in clinical trials for patients with pancreatic cancer who are at high risk of developing post-surgery complications. The treatment involves removing the pancreas and transplanting the patient’s own islet cells, potentially improving outcomes and quality of life for those undergoing pancreatic cancer surgery.

Related diseases and areas:

• Pancreatic carcinoma

Autologous Peripheral Blood-Derived Cd4 And Cd8 T Lymphocytes, Transduced With A Lentiviral Vector To Expressing A Chimeric Receptor Against Bcma With Co-Stimulatory Sequences 4-1-Bb And Cd3 Zeta

A groundbreaking clinical trial is underway to evaluate a new CAR-T cell therapy called HUVR-CARTemis-1 for patients with relapsed multiple myeloma after allogeneic transplant. This innovative treatment uses the patient’s own immune cells, modified to target a specific protein called BCMA, which is found on myeloma cells. The trial aims to assess the feasibility of producing these modified cells and determine their safety and effectiveness in treating this challenging form of blood cancer.

Related diseases and areas:

• Plasma cell myeloma

AUTOLOGOUS REGULATORY T-CELLS WITH AN IMMUNOPHENOTYPE OF CD4+CD25HI/+FOXP3+

Clinical trials are investigating AUTOLOGOUS REGULATORY T-CELLS WITH AN IMMUNOPHENOTYPE OF CD4+CD25HI/+FOXP3+ in adults with ulcerative colitis. These studies aim to assess clinical remission and how the cells behave in the body after transfer. The trial data here describe a phase 2 study with 30 participants.

Related diseases and areas:

• Colitis ulcerative

Autologous Skin-Derived Adult Fibroblasts Expanded

A groundbreaking clinical trial is underway to evaluate the safety and efficacy of a new tissue-engineered autologous skin substitute for reconstructive surgery in patients with basal cell carcinoma. This phase II study aims to explore the potential of nanostructured artificial skin, created using the patient’s own cells, as an alternative to traditional autografts in Mohs surgery. The trial focuses on assessing the safety, feasibility, and effectiveness of this innovative approach in improving patient outcomes and quality of life.

Related diseases and areas:

• Micrographic skin surgery

Autologous Skin-Derived Adult Keratinocytes Expanded

This article discusses a Phase II clinical trial investigating the use of autologous skin-derived adult keratinocytes and fibroblasts for reconstructive surgery in patients with basal cell carcinoma. The study aims to evaluate the safety, feasibility, and efficacy of nanostructured autologous artificial skin based on a fibrin matrix combined with agarose or hyaluronic acid. This innovative approach could potentially improve outcomes for patients undergoing Mohs surgery for basal cell carcinoma.

Related diseases and areas:

• Micrographic skin surgery

Autologous T Cells Expressing Cd8A And A T-Cell Receptor Targeting Mage-A4

This article discusses the ongoing clinical trials investigating the use of ADP-A2M4CD8, a genetically modified autologous T-cell therapy, in treating recurrent ovarian cancer. The SURPASS-3 study aims to evaluate the effectiveness and safety of ADP-A2M4CD8 both as a monotherapy and in combination with nivolumab, an immunotherapy drug. This innovative approach targets MAGE-A4 positive tumors in HLA-A*02 positive patients, offering a potential new treatment option for those with limited alternatives.

Related diseases and areas:

• Ovarian cancer recurrent

AUTOLOGOUS T CELLS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR AGAINST GD2, EX-VIVO EXPANDED

Clinical trials are studying AUTOLOGOUS T CELLS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR AGAINST GD2, EX-VIVO EXPANDED in children and young adults with hard-to-treat cancers. These studies mainly aim to check safety, find the best dose, and look for signs of benefit in relapsed or refractory central nervous system tumors and GD2-positive neuroblastoma or other GD2-positive tumors.

Related diseases and areas:

• Neuroblastoma
• Malignant central nervous s…

Autologous T-Cells Encoding A Chimeric Antigen Receptor Targeting Human B Cell Maturation Antigen

This article discusses clinical trials using autologous T-cells encoding a chimeric antigen receptor (CAR) targeting human B cell maturation antigen (BCMA) for the treatment of multiple myeloma. These innovative trials focus on a promising new therapy called CAR T-cell therapy, which involves modifying a patient’s own immune cells to fight cancer. The trials aim to evaluate the effectiveness and safety of this treatment in patients with relapsed and refractory multiple myeloma, as well as to monitor long-term outcomes in patients who have received CAR T-cell therapy.

Related diseases and areas:

• B-cell lymphoma
• B-cell type acute leukaemia
• Plasma cell myeloma

Autologous T-Cells Ex Vivo Modified With A Lentiviral Vector Encoding A Chimeric Antigen Receptor Specific For Cd1A

This article discusses a groundbreaking clinical trial investigating the use of OC-1, a new type of CAR T-cell therapy, for patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or lymphoma (T-LL). The therapy involves modifying a patient’s own T-cells to target CD1a, a protein found on certain cancer cells. This innovative approach aims to provide a potential treatment option for patients who have not responded to standard therapies.

Related diseases and areas:

• T-cell type acute leukaemia
• Precursor T-lymphoblastic l…

AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING AN ANTI-SLAMF7 CD28/CD3-ZETA CHIMERIC ANTIGEN RECEPTOR

Clinical trials are studying AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING AN ANTI-SLAMF7 CD28/CD3-ZETA CHIMERIC ANTIGEN RECEPTOR in people with multiple myeloma. These studies are looking at feasibility, safety, and antitumor activity, as well as how many patients have a response to treatment. The main target population is patients with multiple myeloma.

Related diseases and areas:

• Plasma cell myeloma

Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19

This article explores the use of autologous T-cells transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) directed against CD19 in clinical trials. This innovative therapy, known as CAR T-cell therapy, is being investigated for various conditions, including relapsed or refractory B-cell malignancies and certain autoimmune diseases. The trials aim to assess the safety, efficacy, and feasibility of this personalized treatment approach in patients who have not responded well to conventional therapies.

Related diseases and areas:

• Follicular lymphoma
• Precursor B-lymphoblastic l…
• Malignant melanoma
• Diffuse large B-cell lymphoma
• Acute lymphocytic leukaemia…
• Chronic lymphocytic leukaem…

AUTOLOGOUS T-CELLS TRANSDUCED WITH THE LENTIVIRAL LV-R11KEA ENCODING T-CELL RECEPTOR TARGETING PATIENT-SPECIFIC TUMOR-ASSOCIATED ANTIGENS

Clinical trials are investigating AUTOLOGOUS T-CELLS TRANSDUCED WITH THE LENTIVIRAL LV-R11KEA ENCODING T-CELL RECEPTOR TARGETING PATIENT-SPECIFIC TUMOR-ASSOCIATED ANTIGENS in people with solid tumors and cutaneous melanoma. These studies are looking at safety, tolerability, and how well the treatment works, including tumor response and progression-free survival.

AUTOLOGOUS TOLEROGENIC DENDRITIC CELLS

Clinical trials of AUTOLOGOUS TOLEROGENIC DENDRITIC CELLS are studying this treatment in people with multiple sclerosis, especially relapsing-remitting multiple sclerosis (RRMS). The main goals are to check whether it helps control disease activity and whether it is safe when used with first-line immunotherapy.

Related diseases and areas:

• Multiple sclerosis
• Nervous system disorder

Autologous Tumor Lysate-Loaded Dendritic Cells

This article examines ongoing clinical trials investigating the use of autologous tumor lysate-loaded dendritic cell vaccines for treating different types of cancer. These innovative immunotherapy treatments aim to harness the power of a patient’s own immune system to fight cancer cells. The trials focus on various cancer types, including neuroendocrine tumors, soft tissue sarcomas, glioblastoma, and colorectal cancer, exploring the safety, efficacy, and potential benefits of this personalized approach to cancer treatment.

Related diseases and areas:

• Colorectal cancer metastatic
• Soft tissue sarcoma
• Glioblastoma
• Neuroendocrine tumour

Autumn Crocus Fresh Flower Fluid Extract (1:15-25), Extraction Solvent Ethanol 96% (V/V)

This article examines the use of Autumn Crocus Fresh Flower Fluid Extract (1:15-25), Extraction Solvent Ethanol 96% (V/V) in clinical trials. This extract, also known as colchicine, is being studied for its potential benefits in treating atrial fibrillation and gout. We’ll explore two ongoing trials that aim to assess the efficacy and safety of this compound in different medical conditions.

Related diseases and areas:

• Atrial fibrillation
• Gout

Avacincaptad Pegol

Clinical trials are studying Avacincaptad Pegol in people with geographic atrophy. These studies mainly look at long-term safety and other research outcomes in patients who completed earlier trial treatment. The data here come from a Phase 3 extension study.

Related diseases and areas:

• Dry age-related macular deg…

Avacopan

Clinical trials are investigating Avacopan in people with ANCA-associated vasculitis, including adults with severe kidney disease and children with active disease. These studies look at how well Avacopan works, how safe it is, and how the body handles it when used with standard treatment.

Related diseases and areas:

• Anti-neutrophil cytoplasmic…

Avalglucosidase Alfa

Clinical trials of Avalglucosidase Alfa are studying how well it works and how safe it is in people with Pompe disease, including babies, children, and adults. These studies look at outcomes such as survival, muscle strength, walking ability, lung function, and side effects. Some trials also focus on long-term access or on people whose condition is stable or getting worse on current treatment.

Related diseases and areas:

• Glycogen storage disease ty…

Avalotcagene Ontaparvovec

Avalotcagene Ontaparvovec is an innovative gene therapy being studied in clinical trials for the treatment of late-onset Ornithine Transcarbamylase (OTC) deficiency. This rare genetic disorder affects the body’s ability to process nitrogen, leading to potentially dangerous ammonia buildup in the blood. The clinical trials aim to evaluate the safety and effectiveness of this therapy in improving OTC function and maintaining safe ammonia levels in patients aged 12 and older.

Related diseases and areas:

• Ornithine transcarbamoylase…

Avapritinib

Clinical trials are investigating Avapritinib in different patient groups, including children with certain solid tumors and adults with mastocytosis. These studies look at safety, dose finding, and how well the treatment works. The trials include early-phase and later-phase research.

Related diseases and areas:

• Neoplasm malignant
• Indolent systemic mastocytosis
• Systemic mastocytosis

Avatrombopag

Avatrombopag is an oral thrombopoietin receptor agonist that has shown promise in treating various conditions associated with low platelet counts. This article explores the use of avatrombopag in clinical trials for conditions such as severe aplastic anemia, immune thrombocytopenia, and chemotherapy-induced thrombocytopenia. We’ll examine its efficacy, safety, and potential benefits for patients with these challenging blood disorders.

Related diseases and areas:

• Immune thrombocytopenia

Avb-101

A groundbreaking clinical trial is underway to evaluate AVB-101, a novel gene therapy for patients with Frontotemporal Dementia caused by Progranulin Mutations (FTD-GRN). This Phase 1/2 study aims to assess the safety and potential effectiveness of AVB-101 when administered directly into the brain. The trial offers hope for individuals affected by this rare form of dementia and their families.

Related diseases and areas:

• Frontotemporal dementia

Avelumab

Clinical trials with Avelumab are studying how well it works in different cancers and how safe it is in specific patient groups. These studies include maintenance treatment, first-line treatment, and combination therapy in adults and children with advanced, metastatic, or recurrent tumors. The trials measure outcomes such as survival, tumor response, disease control, and quality of life.

Related diseases and areas:

• Anal cancer
• Head and neck cancer
• Head and neck cancer metast…
• Squamous cell carcinoma of …
• Bladder cancer
• Triple negative breast cancer

Avibactam Sodium

Clinical trials of Avibactam Sodium are studying aztreonam-avibactam in young patients with serious gram-negative bacterial infections. These studies look at pharmacokinetics, safety, and tolerability in neonates, infants, and children with infections such as sepsis, urinary tract infection, pneumonia, and bloodstream infection.

Related diseases and areas:

• Infection
• Urinary tract infection
• Bacterial infection
• Pneumonia
• Abdominal infection
• Sepsis

AVTX-009

Researchers are currently investigating AVTX-009, a promising new medication for people suffering from moderate to severe Hidradenitis Suppurativa (HS). The LOTUS study is a Phase 2 clinical trial designed to evaluate how effectively and safely AVTX-009 works compared to a placebo. This randomized trial involves different dosing schedules of AVTX-009 administered as subcutaneous injections. Participants will receive treatment for up to 16 weeks, with researchers monitoring improvements in HS symptoms such as reduction in abscesses, inflammatory nodules, and draining fistulas. This trial represents an important step in developing new treatment options for this challenging skin condition.

Related diseases and areas:

• Hidradenitis